Form 4 INCYTE CORP For: Oct 02 Filed by: Denton Sheila A.
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Incyte Co. (NASDAQ: INCY) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $84.00 price target on the stock.MarketBeat
- Incyte Gains 12.7% Year to Date: How Should You Play the Stock? [Yahoo! Finance]Yahoo! Finance
- Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 CongressBusiness Wire
- Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 7/30/24 - Miss
INCY
Sec Filings
- 10/3/24 - Form 4
- 10/3/24 - Form 3
- 10/2/24 - Form 4
- INCY's page on the SEC website